Nordson Q3: Revenue and Operating Profit Rise; ATS Strength, Atrion Deal, Higher Interest Costs

Nordson Corporation (NASDAQ: NDSN) - Q3 FY2025 snapshot
What's happening inside: management is actively reshaping the portfolio (acquired Atrion in 2024; exiting select medical contract manufacturing lines in Q3 2025), continuing share repurchases, and investing in capacity. Results show revenue growth and segment divergence - strong ATS and Asia Pacific demand, offset by higher financing costs and a Q3 divestiture charge.

Key facts & statistics (reported)
* Sales - Q3 ended July 31, 2025: $741,509; Q3 2024: $661,604 (up 12.1%).
* Nine months sales: $2,039,867 vs $1,945,439 (up 4.9%).
* Gross margin - Q3: $406,517 (54.8% vs 55.8% prior year); nine months: 54.7% vs 55.7% (down 1.0 ppt).
* Operating profit - Q3: $187,767 (up 12.4%); nine months: $497,464 (flat +0.5%).
* Net income - Q3: $125,784 (up 7.2%); nine months: $332,840 (down 3.6%).
* EPS (diluted) - Q3: $2.22 vs $2.04; nine months: $5.83 vs $5.99.
* Interest expense - Q3: $26,258 vs $18,803 (↑39.6%); nine months: $79,389 vs $60,354 (↑31.5%).
* Divestiture & related charges - $12,211 recorded in Q3 2025 (non‑cash impairment + exit costs).
* Assets held for sale - $39,583 as of July 31, 2025; liabilities held for sale $10,807.
* Cash & equivalents - $147,788 (July 31, 2025).
* Net cash provided by operations (YTD) - $516,264 (nine months ended July 31, 2025).
* Long‑term debt (carrying) - $2,129,078; long‑term maturities shown net $1,785,745; current maturities jumped to $336,078 (July 31, 2025).
* Share repurchases - 336,368 shares repurchased in Q3 at avg $211.92; nine‑month treasury purchases $218,194.
* Shares outstanding - 56,186,303 (as of August 18, 2025).
* Major acquisition - Atrion (closed Aug 21, 2024): cash consideration $789,996; preliminary goodwill $494,279; identifiable intangibles $129,600.
* Segment Q3 sales / operating profit: IPS $350,784 / $116,720; MFS $219,465 / $52,500; ATS $171,260 / $36,877.
* Regional Q3 sales: Americas $314,568; Europe $186,620; Asia Pacific $240,321.

Positive aspects of the income statement
* Top‑line growth: consolidated sales +12.1% in the quarter, driven by MFS (acquisition) and strong ATS organic demand.
* Operating leverage: Q3 operating profit rose 12.4% to $187.8M and ATS showed substantial margin improvement (ATS operating profit +41.7% YoY).
* Strong operating cash flow: $516.3M YTD provides flexibility for buybacks, capex and debt management.
* Active capital returns: meaningful share repurchases and continued dividend payments demonstrate cash return discipline.

Negative aspects of the income statement
* Margin pressure: gross margin contracted ~1.0 percentage point (Q3 and YTD) - cost inflation or mix effects reducing unit margins.
* Rising interest cost: interest expense materially higher (Q3 +39.6%), largely tied to higher average debt after acquisitions - compresses net income and EPS on a YTD basis.
* One‑time charges: $12.2M divestiture/impairment and related exit charges in Q3 reduced operating income and drove asset/liability reclassification to held‑for‑sale.
* Net income down YTD: despite higher operating profit in Q3, nine‑month net income fell 3.6% (driven by interest and one‑time charges).
* Debt near term: current maturities of long‑term debt rose to $336.1M - watch upcoming maturities and refinancing risk if markets tighten.
* Foreign currency and hedging volatility: other‑net included foreign currency losses that weighed on results.

Operational & strategic notes (inside the company)
* Portfolio actions: management acquired Atrion (medical fluid business) and is exiting select medical contract manufacturing lines - recorded held‑for‑sale and impairment in Q3; that divestiture is expected to close by Q4 2025.
* Segment trends: ATS = strong organic growth and margin improvement; MFS = inorganic lift from Atrion but near‑term destocking/contract manufacturing exit weighed organic MFS results; IPS = mixed with weakness in polymer processing and industrial coatings.
* Cost actions: company cites strategic cost reduction and manufacturing footprint optimization supporting ATS margin gains.
* Capital allocation: heavy buybacks funded by operations and borrowing; board authorized additional $500M repurchase in Aug 2025 (available capacity noted in filing).

What to watch next (key risks & catalysts)
* Completion and proceeds of the planned divestiture (expected by Q4 2025).
* Interest expense trajectory and refinancing risk as near‑term maturities become due.
* Organic demand in IPS and MFS (customer destocking in some medical interventional lines persists).
* Execution of integration benefits from Atrion and whether MFS margins recover after divestiture and restructuring.
* Share count trend given continued repurchases vs. treasury issuance for compensation.

Bottom line: Nordson (NASDAQ: NDSN) delivered solid Q3 revenue and operating profit growth with strong ATS performance and healthy operating cash flow, but rising interest expense, a Q3 divestiture charge and near‑term debt maturities temper the near‑term earnings outlook. Management's portfolio moves (Atrion acquisition + planned divestiture) are reshaping the company - investors should watch cash generation, debt servicing, and the outcome of the divestiture.